drugset / Trial / NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Timeline
- Start
- 2026-01-02
- Primary completion
- 2031-08-12
- Completion
- 2031-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BMS-986504 | Unknown | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Comparator | Pemetrexed | Small molecule | — | — |
Indications
No indication recorded.